+

WO2005076999A3 - Methods and compositions for combination rnai therapeutics - Google Patents

Methods and compositions for combination rnai therapeutics Download PDF

Info

Publication number
WO2005076999A3
WO2005076999A3 PCT/US2005/003858 US2005003858W WO2005076999A3 WO 2005076999 A3 WO2005076999 A3 WO 2005076999A3 US 2005003858 W US2005003858 W US 2005003858W WO 2005076999 A3 WO2005076999 A3 WO 2005076999A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
rnai therapeutics
sirna molecules
combination rnai
Prior art date
Application number
PCT/US2005/003858
Other languages
French (fr)
Other versions
WO2005076999A2 (en
Inventor
Bao-Jian Li
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Original Assignee
Intradigm Corp
Bao-Jian Li
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corp, Bao-Jian Li, Patrick Y Lu, Martin C Woodle, Frank Y Xie filed Critical Intradigm Corp
Priority to CA002555531A priority Critical patent/CA2555531A1/en
Priority to EP05713043A priority patent/EP1713819A4/en
Priority to AU2005213485A priority patent/AU2005213485A1/en
Publication of WO2005076999A2 publication Critical patent/WO2005076999A2/en
Priority to JP2007539358A priority patent/JP2009526516A/en
Priority to EP05857827A priority patent/EP1817416A2/en
Priority to US11/792,179 priority patent/US8691781B2/en
Priority to PCT/US2005/040048 priority patent/WO2006121464A2/en
Priority to CA002586250A priority patent/CA2586250A1/en
Priority to CN2011104403455A priority patent/CN102618541A/en
Priority to CNA2005800450233A priority patent/CN101103111A/en
Publication of WO2005076999A3 publication Critical patent/WO2005076999A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods containing mixtures of siRNA molecules that target genes associated with disease are provided. The mixtures of siRNA molecules provide greater efficacy in reducing expression of disease-associated genes than individual siRNA molecules.
PCT/US2005/003858 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics WO2005076999A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002555531A CA2555531A1 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics
EP05713043A EP1713819A4 (en) 2004-02-05 2005-02-07 METHODS AND COMPOSITIONS FOR COMBINING RNAI TREATMENTS
AU2005213485A AU2005213485A1 (en) 2004-02-05 2005-02-07 Methods and compositions for combination RNAi therapeutics
CNA2005800450233A CN101103111A (en) 2004-11-05 2005-11-04 Composition and use thereof for treating respiratory virus infection
EP05857827A EP1817416A2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
JP2007539358A JP2009526516A (en) 2004-11-05 2005-11-04 Composition for treating respiratory viral infection and use thereof
US11/792,179 US8691781B2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
PCT/US2005/040048 WO2006121464A2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
CA002586250A CA2586250A1 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use
CN2011104403455A CN102618541A (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54177604P 2004-02-05 2004-02-05
US60/541,776 2004-02-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/792,179 Continuation-In-Part US8691781B2 (en) 2004-11-05 2005-11-04 Compositions for treating respiratory viral infections and their use

Publications (2)

Publication Number Publication Date
WO2005076999A2 WO2005076999A2 (en) 2005-08-25
WO2005076999A3 true WO2005076999A3 (en) 2006-07-06

Family

ID=34860217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003858 WO2005076999A2 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics

Country Status (5)

Country Link
EP (1) EP1713819A4 (en)
CN (1) CN101044152A (en)
AU (1) AU2005213485A1 (en)
CA (1) CA2555531A1 (en)
WO (1) WO2005076999A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
CN101103111A (en) 2004-11-05 2008-01-09 因特拉迪格姆公司 Composition and use thereof for treating respiratory virus infection
ES2385811T3 (en) 2005-01-07 2012-08-01 Alnylam Pharmaceuticals Inc. RSV RNAi modulation and therapeutic uses thereof
EP1877065A4 (en) * 2005-04-12 2010-12-22 Intradigm Corp COMPOSITION OF INTERFERENT RNA THERAPEUTIC AGENTS (RNAi) AND METHODS FOR TREATING CANCER AND OTHER NEOVASCULARIZATION DISEASES
WO2007025254A2 (en) * 2005-08-26 2007-03-01 Henry Ford Health System Investigation and treatment of cancer using a g-protien coupled eicosnoid receptor
WO2007080902A1 (en) * 2006-01-11 2007-07-19 Kyowa Hakko Kogyo Co., Ltd. Composition inhibiting the expression of target gene in eyeball and remedy for disease in eyeball
US20100279408A1 (en) * 2006-11-27 2010-11-04 Enzon Pharmaceuticals, Inc. Polymeric short interfering rna conjugates
JP2010512786A (en) * 2006-12-21 2010-04-30 イントラダイム コーポレイション Inhibitory polynucleotide compositions and methods for treating cancer
ES2426684T3 (en) 2007-03-23 2013-10-24 To-Bbb Holding B.V. Conjugates for the targeted delivery of drugs through the blood brain barrier
NZ584827A (en) * 2007-10-01 2012-10-26 Isis Pharmaceuticals Inc Antisense modulation of fibroblast growth factor receptor 4 expression
US8735567B2 (en) 2007-11-06 2014-05-27 Patrick Y. Lu Multi-targeted RNAi therapeutics for scarless wound healing of skin
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
CN102985546A (en) 2010-05-04 2013-03-20 圣诺制药公司 Combinations of TGF-beta and Cox-2 inhibitors and methods for their therapeutic application
WO2012016139A2 (en) 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
JP6043347B2 (en) 2011-06-16 2016-12-14 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Antisense regulation of fibroblast growth factor receptor 4 expression
CN103007291B (en) * 2011-09-26 2015-04-29 苏州圣诺生物医药技术有限公司 Composition for treating eye diseases by double-target/multi-target small nucleic acid and applications of composition
CN102399820B (en) * 2011-09-27 2013-06-12 天津佰思普生物科技有限公司 Small interfering RNA directed at HPV16 E7 gene and its application
WO2014011512A1 (en) 2012-07-08 2014-01-16 Sirnaomics, Inc. Compositions and methods for "resistance-proof" sirna therapeutics for influenza
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
CN110177544A (en) 2016-11-29 2019-08-27 普尔泰克健康有限公司 For delivering the excretion body of therapeutic agent
CN106771252A (en) * 2017-01-13 2017-05-31 福建医科大学 Application and kit of the AMACR albumen in prognosis evaluation reagent kit after preparing Liver Cancer Operation
CN111620939B (en) * 2019-10-25 2021-01-01 南京市妇幼保健院 A polypeptide ZYX36-58 for the treatment or adjuvant treatment of ovarian cancer
BR112022014578A2 (en) 2020-01-23 2022-09-13 Sirnaomics Inc COMPOSITION AND METHODS OF PROPHYLATIC AND THERAPEUTIC RNAI FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY INFECTION CAUSED BY THE NEW CORONA VIRUS 2019 (2019-NCOV)
CN114196785A (en) * 2020-09-18 2022-03-18 北京大学人民医院 Biomarkers of cytomegalovirus susceptibility to megakaryocytes after allogeneic hematopoietic stem cell transplantation and its application
CN114452393A (en) * 2022-02-22 2022-05-10 南方科技大学 Application of PINCH-1 protein as target in preparation of medicine for treating pulmonary fibrosis
CN116421616A (en) * 2022-03-17 2023-07-14 圣诺生物医药技术(苏州)有限公司 A nucleic acid interference pharmaceutical composition and medicines for treating colorectal cancer, gastric cancer and prostate cancer
CN116983322A (en) * 2022-09-15 2023-11-03 圣诺生物医药技术(苏州)有限公司 Small nucleic acid interference medicine for treating lung cancer, pancreatic cancer, liver cancer and colorectal cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033602A1 (en) * 2002-06-12 2004-02-19 Ambion, Inc. Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
CN1922330A (en) * 2003-04-25 2007-02-28 因特拉迪格姆公司 Rnai agents for anti-sars coronavirus therapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] "Homo sapiens epidermal growth factor (EGF) mRNA sequence", XP003019070, Database accession no. (NM_001963) *
DATABASE GENBANK [online] "Homo sapiens vascular endothelial growth factor receptor 2 (KDR) mRNA sequence", XP003019069, Database accession no. (AF063658) *
DOWNWARD J.: "Science, medicine, and the future: RNA interference", BMJ, vol. 328, 2004, pages 1245 - 1248, XP003002362 *
ELBASHIR ET AL.: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, 24 May 2001 (2001-05-24), pages 494 - 498, XP001167187 *
HAMMOND ET AL.: "Post-Transcriptional gene silencing by double-stranded RNA", NATURE REVIEWS, vol. 2, February 2001 (2001-02-01), pages 110 - 119, XP001146153 *
HANNON ET AL.: "Unlocking the potential of the human genome with RNA interference", NATURE, vol. 431, 2004, pages 371 - 378, XP003002623 *
ISHIBASHI ET AL.: "Expression cloning of a human dual-specificity phosphatase", PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 12170 - 12174, XP008072750 *
PAROO ET AL.: "Challenges for RNAi in vivo", TRENDS IN BIOTECHNOLOGY, vol. 22, August 2004 (2004-08-01), pages 390 - 394, XP002299924 *
See also references of EP1713819A4 *
SHIRAI ET AL.: "Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor", NATURE, vol. 313, no. 6005, 28 February 1985 (1985-02-28), pages 803 - 806, XP002140139 *

Also Published As

Publication number Publication date
WO2005076999A2 (en) 2005-08-25
EP1713819A2 (en) 2006-10-25
CA2555531A1 (en) 2005-08-25
EP1713819A4 (en) 2007-11-14
AU2005213485A1 (en) 2005-08-25
CN101044152A (en) 2007-09-26

Similar Documents

Publication Publication Date Title
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
IL181238A (en) Sirna molecules that inhibit rtp801 gene expression and therapeutic uses thereof
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
EP2395012B8 (en) Modified siRNA molecules and uses thereof
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
IL250678A0 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2010033225A3 (en) Compositions and methods for the specific inhibition of gene expression by dsrna
MX348735B (en) MESENCHYMAL STEM CELLS EXPRESSING TNF-a RECEPTOR.
WO2009151546A3 (en) Methods for treating spinal muscular atrophy
IL231688A0 (en) Dsrna for inhibiting the expression of human eg5 gene in a cell, a pharmaceutical composition comprising same, a method and vector
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2008131419A3 (en) Glycoconjugates of rna interference agents
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2006029258A3 (en) Aptamer medicinal chemistry
WO2007014075A3 (en) Rnai modulation of the rho-a gene in research models
WO2007092182A3 (en) Rna interference agents for therapeutic use
EP1819365A4 (en) COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE IN MAMMALS AND METHODS FOR PREVENTING AN IMMUNE RESPONSE DIRECTED AGAINST OLIGONUCLEOTIDE AGENTS, IN PARTICULAR SHORT INTERFERING RNA
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2009111586A3 (en) Autonomous in vitro evolution
GB0602992D0 (en) Methods, genes and proteins
WO2005118824A3 (en) Methods and compositions for the inhibition of gene expression
WO2005117557A3 (en) Expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2555531

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005713043

Country of ref document: EP

Ref document number: 2005213485

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005213485

Country of ref document: AU

Date of ref document: 20050207

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005213485

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580011956.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005713043

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载